BX-471 - CAS# 217645-70-0 60310 InChi: InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22

InChi: InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22

At 18 months

InChiKey: MVOZLTFXYGHZPM-UHFFFAOYSA-N

Saracatinib binds to and inhibits these tyrosine kinases and their effects on cell motility

SR9243 kills cancer cells by inhibiting lipid production and the Warburg effect

BX-471 - CAS# 217645-70-0 60310 InChi: InChI=1S/C62H86N12O16/c1-27(2)42-59(84)73-23-17-19-36(73)57(82)69(13)25-38(75)71(15)48(29(5)6)61(86)88-33(11)44(55(80)65-42)67-53(78)35-22-21-31(9)51-46(35)64-47-40(41(63)50(77)32(10)52(47)90-51)54(79)68-45-34(12)89-62(87)49(30(7)8)72(16)39(76)26-70(14)58(83)37-20-18-24-74(37)60(85)43(28(3)4)66-56(45)81/h21-22BX 471, CAS No. 217645 70 0, also known as ZK 811752, is a potent, selective non peptide CCR1 antagonist (Ki = 1 nM for human CCR1). BX 471 exhibits 250 fold selectivity for CCR1 over CCR2, CCR5 and CXCR4. BX 471 was developed Berlex and its parent company, Schering AG. BX 471 is the lead in a series of non peptide chemokine receptor 1 (CCR1) antagonists, for the potential treatment of autoimmune diseases, in particular multiple sclerosis (MS). In